Home / Methotrexate / United States
US ATC L01BA01 · updated 2 Nov 2026
Methotrexate shortage in United States
Is there a Methotrexate shortage in United States?
Yes. As of 2 Nov 2026, 15 Methotrexate products are reported short in United States, the first since 13 Mar 2023. No return date has been given. Main reason: not stated.
Also short in Canada, France, Spain, Ireland, Belgium. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | Accord Healthcare Inc. | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | Accord Healthcare Inc. | 13 Mar 2023 | not given | Other |
| US | Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) | Hikma Pharmaceuticals USA, Inc. | 13 Mar 2023 | not given | Increased demand Demand increase for the drug |
| US | Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) | Hikma Pharmaceuticals USA, Inc. | 13 Mar 2023 | not given | Increased demand Demand increase for the drug |
| US | Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | Fresenius Kabi USA, LLC | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) limited | Teva Pharmaceuticals USA, Inc. | 13 Mar 2023 | not given | Other |
| US | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | Teva Pharmaceuticals USA, Inc. | 13 Mar 2023 | not given | Other |
| US | Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) limited | Teva Pharmaceuticals USA, Inc. | 13 Mar 2023 | not given | Other |
| US | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) | Fresenius Kabi USA, LLC | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
| US | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05) | Hospira, Inc., a Pfizer Company | 13 Mar 2023 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).